Olatec Therapeutics, LLC
Olatec is a biopharmaceutical company dedicated to improving health through the development of safe and effective pharmaceuticals targeting inflammatory diseases. They focus on NLRP3 inflammasome inhibitors, with their lead compound dapansutrile (OLT1177®), which has shown clinical benefits in various inflammatory conditions. The company conducts operations in the US and Europe, with a team of experienced management and thought leaders in inflammation and immunology.
Industries
Nr. of Employees
small (1-50)
Olatec Therapeutics, LLC
Based in the Greater New York area, specific address not provided.
Products
Dapansutrile (selective NLRP3 inhibitor)
Oral small-molecule inhibitor that selectively targets NLRP3 to prevent inflammasome formation and reduce production of IL-1β and IL-18; advanced clinical-stage candidate being evaluated in multiple inflammatory indications.
Dapansutrile (selective NLRP3 inhibitor)
Oral small-molecule inhibitor that selectively targets NLRP3 to prevent inflammasome formation and reduce production of IL-1β and IL-18; advanced clinical-stage candidate being evaluated in multiple inflammatory indications.
Services
Design and conduct of early-phase human studies (safety, pharmacodynamics, proof-of-concept) using randomized, dose-escalation and dose-adaptive methodologies.
Preclinical efficacy studies in multiple disease models to assess target engagement, functional protection and disease-modifying potential.
Synthesis and early screening of structurally related compound series to optimize potency, selectivity and drug-like properties.
Regulatory planning and document preparation informed by team experience drafting IND/NDA/BLA/MAA-style submissions and interacting with regulatory agencies.
Design and conduct of early-phase human studies (safety, pharmacodynamics, proof-of-concept) using randomized, dose-escalation and dose-adaptive methodologies.
Preclinical efficacy studies in multiple disease models to assess target engagement, functional protection and disease-modifying potential.
Synthesis and early screening of structurally related compound series to optimize potency, selectivity and drug-like properties.
Regulatory planning and document preparation informed by team experience drafting IND/NDA/BLA/MAA-style submissions and interacting with regulatory agencies.
Expertise Areas
- Small-molecule drug discovery for innate immunity targets
- Preclinical disease-model evaluation
- Early-phase clinical trial management
- Translational pharmacology and biomarker development
Key Technologies
- NLRP3 inflammasome inhibition
- Small-molecule medicinal chemistry
- Animal disease models (murine)
- Cytokine biomarker assays (IL-1β, IL-18)
News & Updates
OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation.
Clinical trial demonstrating the efficacy of dapansutrile in treating gout flares.
Preclinical study showing the effectiveness of OLT1177 in reducing joint inflammation.
Clinical Trials of Dapansutrile
Completed six clinical trials for dapansutrile, demonstrating safety and efficacy.
Patent Portfolio
Maintains an extensive portfolio of over 180 patents and patent applications globally.
OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation.
Clinical trial demonstrating the efficacy of dapansutrile in treating gout flares.
Preclinical study showing the effectiveness of OLT1177 in reducing joint inflammation.
Clinical Trials of Dapansutrile
Completed six clinical trials for dapansutrile, demonstrating safety and efficacy.
Patent Portfolio
Maintains an extensive portfolio of over 180 patents and patent applications globally.